Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > How Barclays Capital values Small Cap Oncology names

<< Previous

Bullboard Posts

Next >>

Comment by jfm1330on Feb 04, 2021 2:19pm

110 Views

Post# 32472244

RE:RE:RE:RE:RE:RE:RE:RE:How Barclays Capital values Small Cap Oncology names

Another thing. To those deploring the supposedly poor job of Thera in making their programs known. With today's news, you can be sure that the oncology program is now known to all serious investors in biopharma. These investors specialized in biopharma do at least a quick review of all the drug candidates getting fast track status from the FDA. That does not mean they will jump on the stock today, but it was on their radar screen today and some will take a closer look at it. It is possible that we will see a delayed positive reaction.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China